Association Between Statin Use and Daptomycin-related Musculoskeletal Adverse Events: A Mixed Approach Combining a Meta-analysis and a Disproportionality Analysis.
Adverse Drug Reaction Reporting Systems
Atorvastatin
Daptomycin
/ adverse effects
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
/ adverse effects
Muscular Diseases
/ chemically induced
Rhabdomyolysis
/ chemically induced
Rosuvastatin Calcium
/ adverse effects
Simvastatin
/ adverse effects
United States
/ epidemiology
United States Food and Drug Administration
daptomycin
disproportionality analysis
meta-analysis
musculoskeletal adverse event
statin
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
12 10 2022
12 10 2022
Historique:
received:
04
11
2021
pubmed:
10
3
2022
medline:
15
10
2022
entrez:
9
3
2022
Statut:
ppublish
Résumé
There is a growing concern about the association between the combined use of daptomycin (DAP) and statins and the occurrence of musculoskeletal adverse events (MAEs), but this remains controversial. This study aimed to clarify the association between statin use and DAP-related MAEs. We used a mixed approach that combines 2 methodologies. First, we conducted a meta-analysis to examine the effects of statin use on DAP-related MAEs. Second, we conducted a disproportionality analysis using the US Food and Drug Administration Adverse Events Reporting System (FAERS) to further confirm the results of the meta-analysis and to examine the effect of each type of statin on DAP-related MAEs in a large population. In the meta-analysis, statin use significantly increased the incidence of DAP-related rhabdomyolysis (odds ratio [OR]: 3.83; 95% confidence interval [CI]: 1.43-10.26) but not DAP-related myopathy (OR: 1.72; 95% CI: .95-3.12). In the disproportionality analysis using the FAERS, the use of statin significantly increased the reporting OR (ROR) for DAP-related myopathy (ROR: 5.69; 95% CI: 4.31-7.51) and rhabdomyolysis (ROR: 5.77; 95% CI: 4.33-7.68). Atorvastatin, rosuvastatin, and simvastatin all increased the incidence of DAP-related myopathy and rhabdomyolysis. The mixed approach combining a meta-analysis and disproportionality analysis showed that statin use was associated with the occurrence of DAP-related rhabdomyolysis. The appropriate use of statins and DAP should be performed with careful consideration of its safety.
Sections du résumé
BACKGROUND
There is a growing concern about the association between the combined use of daptomycin (DAP) and statins and the occurrence of musculoskeletal adverse events (MAEs), but this remains controversial. This study aimed to clarify the association between statin use and DAP-related MAEs.
METHODS
We used a mixed approach that combines 2 methodologies. First, we conducted a meta-analysis to examine the effects of statin use on DAP-related MAEs. Second, we conducted a disproportionality analysis using the US Food and Drug Administration Adverse Events Reporting System (FAERS) to further confirm the results of the meta-analysis and to examine the effect of each type of statin on DAP-related MAEs in a large population.
RESULTS
In the meta-analysis, statin use significantly increased the incidence of DAP-related rhabdomyolysis (odds ratio [OR]: 3.83; 95% confidence interval [CI]: 1.43-10.26) but not DAP-related myopathy (OR: 1.72; 95% CI: .95-3.12). In the disproportionality analysis using the FAERS, the use of statin significantly increased the reporting OR (ROR) for DAP-related myopathy (ROR: 5.69; 95% CI: 4.31-7.51) and rhabdomyolysis (ROR: 5.77; 95% CI: 4.33-7.68). Atorvastatin, rosuvastatin, and simvastatin all increased the incidence of DAP-related myopathy and rhabdomyolysis.
CONCLUSION
The mixed approach combining a meta-analysis and disproportionality analysis showed that statin use was associated with the occurrence of DAP-related rhabdomyolysis. The appropriate use of statins and DAP should be performed with careful consideration of its safety.
Identifiants
pubmed: 35262686
pii: 6545825
doi: 10.1093/cid/ciac128
pmc: PMC9555841
doi:
Substances chimiques
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Rosuvastatin Calcium
83MVU38M7Q
Atorvastatin
A0JWA85V8F
Simvastatin
AGG2FN16EV
Daptomycin
NWQ5N31VKK
Types de publication
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1416-1422Informations de copyright
© The Author(s) 2022. Published by Oxford University Press for the Infectious Diseases Society of America.
Déclaration de conflit d'intérêts
Potential conflicts of interest. Y. T. received speaker fees from Daiichi-Sankyo Co., Ltd. The other authors have no conflicts of interest to declare. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Références
Br J Clin Pharmacol. 2022 Mar;88(3):1211-1222
pubmed: 34436795
Clin Ther. 2004 Nov;26(11):1728-57
pubmed: 15639687
Arterioscler Thromb Vasc Biol. 2019 Feb;39(2):e38-e81
pubmed: 30580575
Am J Cardiovasc Drugs. 2018 Jun;18(3):157-173
pubmed: 29318532
Int Orthop. 2013 Jul;37(7):1375-80
pubmed: 23519823
Ann Intern Med. 2009 Aug 18;151(4):W65-94
pubmed: 19622512
Ann Pharmacother. 2014 Mar;48(3):320-7
pubmed: 24321853
BMC Infect Dis. 2013 Feb 04;13:66
pubmed: 23379510
Arch Cardiovasc Dis. 2020 Jun - Jul;113(6-7):420-432
pubmed: 32418884
Kidney Int. 2021 Apr;99(4):885-899
pubmed: 33307103
Clin Infect Dis. 2004 Jun 15;38(12):1673-81
pubmed: 15227611
J Antimicrob Chemother. 2000 Oct;46(4):523-6
pubmed: 11020247
Infect Dis Ther. 2014 Dec;3(2):225-33
pubmed: 25245515
JAMA. 2014 Jul;312(2):129-30
pubmed: 25005647
J Clin Epidemiol. 2013 Apr;66(4):408-14
pubmed: 23337781
Control Clin Trials. 1986 Sep;7(3):177-88
pubmed: 3802833
Chest. 2018 Jul;154(1):136-147
pubmed: 29275134
J Clin Med. 2017 Jul 25;6(8):
pubmed: 28757597
Open Forum Infect Dis. 2019 Nov 07;6(11):ofz444
pubmed: 31723571
Neuromuscul Disord. 2014 Aug;24(8):651-9
pubmed: 24946698
JAMA Oncol. 2018 Aug 1;4(8):1112-1115
pubmed: 29327061
Clin Infect Dis. 2011 Feb 1;52(3):285-92
pubmed: 21217178
Eur J Clin Microbiol Infect Dis. 2012 Aug;31(8):1771-4
pubmed: 22160888
Basic Clin Pharmacol Toxicol. 2021 Sep;129(3):268-272
pubmed: 34117712
Arch Intern Med. 2004 Oct 25;164(19):2162-8
pubmed: 15505131
Clin Infect Dis. 2018 Oct 15;67(9):1356-1363
pubmed: 29668884
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
Neurology. 2007 Aug 28;69(9):904-10
pubmed: 17724294
Antimicrob Agents Chemother. 2014 Oct;58(10):5726-31
pubmed: 25022580